-
Protein glycosylation in cardiovascular health and disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-18 John C. Chatham, Rakesh P. Patel
-
Imaging cAMP nanodomains in human iPSC-derived cardiomyocytes Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-15 Camille Charrière
In this Tools of the Trade article, Charrière describes the FluoStep FRET-based biosensor used for high-resolution imaging of cAMP nanodomains that are involved in intracellular signalling in cardiomyocytes.
-
Novel cardiovascular therapeutics and the risk of financial toxicity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-14 Alexander H. Gunn, Akshay Pendyal
Novel cardiovascular therapeutics have the potential to improve health outcomes, but financial toxicity from high out-of-pocket costs can limit the reach of these medications and worsen existing health disparities. Understanding the phenomenon of financial toxicity in treating cardiovascular disease is crucial to achieving health equity.
-
Modelling pre-eclampsia and its cardiovascular effects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-13 Sol Olivera, Delyth Graham
In this Tools of the Trade article, Olivera describes a rat model of pre-elampsia that has been instrumental for investigating potential long-term cardiovascular effects in offspring.
-
An epigenome editing approach induces durable silencing of Pcsk9 Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-13 Irene Fernández-Ruiz
A new approach to modify the epigenome can lead to durable silencing of Pcsk9 in mice, thereby reducing plasma LDL-cholesterol levels, according to a study published in Nature.
-
Tackling inflammation in atherosclerosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-12 Mohsen Shoaran, Pasquale Maffia
Shoaran and Maffia recount how our understanding of the role of inflammation in atherosclerosis has evolved and highlight the study by Göran Hansson and colleagues that provided the first hint of the involvement of the adaptive immune response in atherosclerosis.
-
Sex-related similarities and differences in responses to heart failure therapies Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-08 Janice Y. Chyou, Hailun Qin, Javed Butler, Adriaan A. Voors, Carolyn S. P. Lam
-
Cardiac memory: a phenomenon with important clinical implications Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-07 Rebecca J. Gilchrist
Rebecca Gilchrist discusses the study that demonstrated the long-term modulation of ventricular repolarization by the sequence of electrical activation in the human heart and established the concept of cardiac memory.
-
Metabolic product of excess niacin is linked to increased risk of cardiovascular events Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-03-04 Gregory B. Lim
A metabolic product of excess niacin promotes vascular inflammation in preclinical models and is associated with increased rates of major adverse cardiovascular events in humans.
-
Novel drug therapies for atrial fibrillation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-28 Felix Wiedmann, Constanze Schmidt
-
Pulmonary vascular compliance predicts response to VAD support Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-22 Karina Huynh
Using a porcine model of cardiogenic shock, Lamberti and colleagues develop a clinically accessible, patient-validated metric to assess pulmonary vascular compliance that can predict tolerance to left-sided ventricular assist device support.
-
Heartbeat-induced pressure pulsations in cerebral arteries modulate neuronal activity Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-19 Karina Huynh
Heartbeat-induced pressure pulsations within arterial vessels in the brain can directly stimulate central neuronal activity by activating mechanosensitive channels in subsets of neurons, according to a study published in Science.
-
Weight loss from surgery or drug therapy reduces blood pressure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-19 Gregory B. Lim
Two studies indicate that a reduction in body mass index as a result of either bariatric surgery or pharmacological therapy is associated with a blood pressure-lowering effect.
-
DYRK1A gene linked to heart defects in Down syndrome Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-07 Irene Fernández-Ruiz
A study shows that congenital heart defects in Down syndrome are in part caused by increased dosage of the DYRK1A gene, which lies on chromosome 21, leading to reduced proliferation and mitochondrial dysfunction in cardiomyocytes.
-
Iron deficiency and supplementation in heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-02-07 Samira Lakhal-Littleton, John G. F. Cleland
-
Ultra-processed foods and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-30 Fernanda Rauber, Renata Bertazzi Levy
-
Immune checkpoints in cardiac physiology and pathology: therapeutic targets for heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-26 Tamás G. Gergely, Zsófia D. Drobni, Marinos Kallikourdis, Han Zhu, Wouter C. Meijers, Tomas G. Neilan, Tienush Rassaf, Péter Ferdinandy, Zoltán V. Varga
-
The role of the molecular autopsy in sudden cardiac death in young individuals Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-23 Julia C. Isbister, Christopher Semsarian
-
Partial heart transplantation: a new option for paediatric heart valve replacement Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-23 Taufiek K. Rajab, Andrew D. Vogel, Joseph W. Turek
Heart valve replacement in newborn babies remains an unsolved problem because currently used heart valve implants do not grow. This lack of implant growth mandates serial re-operations until adult-size valve implants can be fitted. Partial heart transplantation is a new approach to solve this problem by transplanting only the part of the heart that contains the necessary valve.
-
Fibroblast-like cells promote plaque stability in response to anti-IL-1β therapy Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-23 Gregory B. Lim
Anti-inflammatory therapy involving IL-1β inhibition might reduce the risk of cardiovascular events in individuals with clonal haematopoiesis by increasing the number of fibroblast-like cells in the fibrous cap region of atherosclerotic plaques, thereby stabilizing the plaque and reducing the likelihood of rupture.
-
Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-12 Gabrielle Fredman, Charles N. Serhan
-
Atherosclerotic plaque stabilization and regression: a review of clinical evidence Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-04 Ashish Sarraju, Steven E. Nissen
-
Improving medication adherence in cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-03 Adam J. Nelson, Neha J. Pagidipati, Hayden B. Bosworth
-
Immune and inflammatory mechanisms in hypertension Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-03 Tomasz J. Guzik, Ryszard Nosalski, Pasquale Maffia, Grant R. Drummond
-
Cardiovascular autonomic dysfunction in post-COVID-19 syndrome: a major health-care burden Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-02 Artur Fedorowski, Alessandra Fanciulli, Satish R. Raj, Robert Sheldon, Cyndya A. Shibao, Richard Sutton
-
RNA-binding proteins in cardiovascular biology and disease: the beat goes on Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-02 Mirko Völkers, Thomas Preiss, Matthias W. Hentze
-
Programmed death of macrophages in atherosclerosis: mechanisms and therapeutic targets Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2024-01-02 Guido R. Y. De Meyer, Michelle Zurek, Pauline Puylaert, Wim Martinet
-
Bone marrow adipocytes support fatty acid metabolism during MI-mediated emergency haematopoiesis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-19 Karina Huynh
During myocardial infarction, haematopoietic stem and progenitor cells increase fatty acid oxidation, and bone marrow adipocytes can act as a local energy resource for these cells.
-
Left atrial appendage occlusion Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-19 Jacqueline Saw
Left atrial appendage occlusion (LAAO) has been rapidly adopted for stroke prevention in patients with non-valvular atrial fibrillation and a contraindication to oral anticoagulation. Ongoing and planned clinical trials on LAAO and the development of new devices might expand clinical indications and address the remaining challenges of device-related thrombus and peridevice leak.
-
Photoacoustic method enables deep imaging of blood flow Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-15 Irene Fernández-Ruiz
A method named photoacoustic vector tomography now enables the quantification of haemodynamics in veins at depths of more than 5 mm below the skin surface, outperforming current pure optical modalities for deep haemodynamic imaging.
-
Clonal expansion of CD8+ T cells in aged mice linked to pro-atherogenic phenotype Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-08 Karina Huynh
In aged mice, but not young mice, with atherosclerosis, depletion of CD8+ T cells significantly reduces atherosclerotic lesion size and necrotic core area.
-
Levothyroxine supplementation does not improve heart transplantation from brain-dead donors Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-08 Gregory B. Lim
The use of intravenous levothyroxine does not increase the likelihood of hearts being transplanted from haemodynamically unstable, brain-dead potential donors, suggesting that current practice recommendations should be revised.
-
Not a spectator sport: improving participation of Black patients in cardiovascular clinical trials Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-07 LaPrincess C. Brewer, Joshua J. Joseph
Representation of Black patients in cardiovascular clinical trials remains dismally low, reflective of systemic and structural barriers, which can lead to missed opportunities to meet community-identified needs, understand responses to medical therapies and improve cardiovascular care. Innovative, multilevel strategies focused on Black communities are warranted to increase enrolment of this population
-
Mosaic loss of chromosome Y and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-06 Soichi Sano, Kenneth Walsh
-
Anticoagulation in patients with atrial high-rate episodes Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-07 Tatjana Potpara, Carina Blomstrom-Lundqvist
-
Base editing therapy corrects long QT syndrome in mice Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-05 Irene Fernández-Ruiz
Gene therapy involving adenine base editing can correct a pathogenic variant in the Scn5a gene and alleviate arrhythmia phenotypes in a mouse model of long QT syndrome type 3.
-
The case for eliminating racial and ethnic cardiovascular disparities in the USA Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-05 Keith C. Ferdinand
Racial and ethnic disparities in cardiovascular health in the USA result in a persistent mortality gap between white and Black individuals, increase health-care costs and compromise an egalitarian society. Solutions to racial inequities require risk factor control and the implementation of evidence-based medicine and anti-racism policies. Overcoming these disparities is not only a practical necessity
-
PCI for stable angina Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-30 Gregory B. Lim
In the ORBITA-2 trial, percutaneous coronary intervention was associated with a lower angina symptom score compared with a placebo procedure in patients with stable angina who were receiving minimal or no antianginal medication.
-
Non-invasive ultrasound therapy for calcified aortic valve stenosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-30 Karina Huynh
In patients with severe calcified aortic valve stenosis, treatment with transthoracically delivered non-invasive ultrasound is safe and improves valve function.
-
MINT trial signals potential benefit of liberal transfusion strategy in MI with anaemia Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-30 Irene Fernández-Ruiz
A liberal strategy of blood transfusion might improve outcomes in patients with acute myocardial infarction and anaemia, according to results from the MINT trial.
-
New insights into dietary cholesterol absorption Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-12-01 Jennifer Harman
Aster proteins are involved in the non-vesicular transport of cholesterol derived from dietary lipids in the small intestine from the plasma membrane to the endoplasmic reticulum in enterocytes.
-
SELECT shows cardiovascular risk reduction with weight-loss drug semaglutide in people without diabetes Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-30 Irene Fernández-Ruiz
Treatment with the glucagon-like peptide 1 receptor agonist semaglutide, administered subcutaneously at a dose of 2.4 mg once per week, reduces the risk of major cardiovascular events by 20% compared with placebo in patients who are overweight or obese and with pre-existing cardiovascular disease but without diabetes mellitus, according to findings from the SELECT trial.
-
Self-monitoring strategy reduces postpartum hypertension and cardiac remodelling Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-28 Karina Huynh
In women with elevated levels of blood pressure during pregnancy, the use of a physician-guided remote telemonitoring programme during the postpartum period improves BP control, according to findings from the POP-HT trial.
-
Aspirin exclusion in patients with an LVAD Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-27 Gregory B. Lim
Data from the ARIES-HM3 trial show that excluding aspirin from the antithrombotic regimen in patients with advanced heart failure and a left ventricular assist device reduces the number of bleeding events and does not increase the risk of thromboembolism.
-
Coronary microvascular obstruction and dysfunction in patients with acute myocardial infarction Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-24 Mattia Galli, Giampaolo Niccoli, Gianluigi De Maria, Salvatore Brugaletta, Rocco A. Montone, Rocco Vergallo, Stefano Benenati, Giulia Magniani, Domenico D’Amario, Italo Porto, Francesco Burzotta, Antonio Abbate, Dominick J. Angiolillo, Filippo Crea
-
Long non-coding RNAs in cardiac hypertrophy and heart failure: functions, mechanisms and clinical prospects Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-20 John D. Mably, Da-Zhi Wang
-
Explaining how a cardiac reflex causes syncope Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-14 Gregory B. Lim
Activation of a specific set of vagal sensory neurons connecting the ventricular wall of the heart to the area postrema in the brainstem causes mice to faint. This finding defines a cardiac reflex that recapitulates characteristics of human syncope.
-
Revealing the structure of the cardiac myosin filament Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-14 Gregory B. Lim
Two new studies using cryo-electron microscopy describe the structure and conformation of myosin in the cardiac thick filaments and how it interacts with other thick-filament proteins, such as titin and cardiac myosin-binding protein C, in mammalian hearts.
-
Disrupting a cell-specific miRNA–CXCR4 interaction is atheroprotective in mice Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-13 Irene Fernández-Ruiz
An approach that increases the expression of the chemokine receptor CXCR4 in vascular cells by targeting a microRNA-based repressive pathway attenuates atherosclerosis in mice and promotes atheroprotective functions in human and mouse vascular cells in vitro.
-
Lipoprotein(a), platelet function and cardiovascular disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-08 Harpreet S. Bhatia, Richard C. Becker, Gregor Leibundgut, Mitul Patel, Paul Lacaze, Andrew Tonkin, Jagat Narula, Sotirios Tsimikas
-
Patisiran is beneficial for the treatment of TTR cardiac amyloidosis Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-06 Irene Fernández-Ruiz
Treatment with the small interfering RNA patisiran preserves functional capacity and improves health status and quality of life in patients with transthyretin cardiac amyloidosis, according to data from the 12-month double-blind period of the ongoing APOLLO-B trial.
-
Drug-eluting resorbable scaffolds are superior to angioplasty for infrapopliteal artery disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-06 Karina Huynh
In the LIFE-BTK trial, treatment with an everolimus-eluting resorbable scaffold was superior to angioplasty in improving clinical outcomes in patients with chronic limb-threatening ischaemia due to infrapopliteal artery disease.
-
Long-term outcomes and device failure after TAVI Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-03 Marco Barbanti, John G. Webb
-
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-03 Stefano Toldo, Antonio Abbate
-
2023 World Heart Federation guidelines for the echocardiographic diagnosis of rheumatic heart disease Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-11-02 Joselyn Rwebembera, James Marangou, Julius Chacha Mwita, Ana Olga Mocumbi, Cleonice Mota, Emmy Okello, Bruno Nascimento, Lene Thorup, Andrea Beaton, Joseph Kado, Alexander Kaethner, Raman Krishna Kumar, John Lawrenson, Eloi Marijon, Mariana Mirabel, Maria Carmo Pereira Nunes, Daniel Piñeiro, Fausto Pinto, Kate Ralston, Craig Sable, Amy Sanyahumbi, Anita Saxena, Karen Sliwa, Andrew Steer, Satupaitea
-
Restoration of flow in the aorta: a novel therapeutic target in aortic valve intervention Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-25 Pankaj Garg, Michael Markl, Janarthanan Sathananthan, Stephanie L. Sellers, Chris Meduri, João Cavalcante
-
Defining iron deficiency in patients with heart failure Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-24 John G. F. Cleland
-
Sirtuin 2 protects against cardiac ageing Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-18 Irene Fernández-Ruiz
NAD-dependent protein deacetylase sirtuin 2 is a key protective mediator against cardiac ageing, according to a study in non-human primates.
-
SARS-CoV-2 infects macrophages in coronary atherosclerotic plaques Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-18 Gregory B. Lim
SARS-CoV-2 infects macrophages, especially lipid-laden foam cells, in coronary atherosclerotic plaques in patients with COVID-19; this infection initiates a strong proatherogenic inflammatory response, which might contribute to the ischaemic cardiovascular complications in these patients.
-
Depolarization of fibroblasts in scar tissue drives cardiac excitation Nat. Rev. Cardiol. (IF 49.6) Pub Date : 2023-10-17 Karina Huynh
In a study published in Science, Wang and colleagues show that excited cardiomyocytes couple to fibroblasts via gap-junctional and non-gap-junctional (ephaptic) coupling.